MONOCLONAL ANTIBODY FOR DIFFERENTIATION OF SQUAMOUS CELL CARCINOMA ANTIGENS AND METHOD OF USE FOR SAME

Abstract: The invention is a monoclonal antibody (MAb 174H.64) which selectively recognizes antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium. In well differentiated squamous cell carcinoma tumors, the antibody preferentially binds with the peripheral proliferative compartment of the tumor. The antigens recognized by MAb 174H.64 include cytoskeletal proteins with molecular weight of approximately 48 to 50kD and 57kD. The method of use of the antibody includes diagnosis of squamous cell carcinoma tumours by immunohistology, non-invasive diagnostic imaging in vivo, treatment of squamous cell carcinoma tumours using MAb conjugates of radionuclide or cytotoxic drugs, all immunopurification of SCC antigens.

Description: M0N0CL0NAL ANTIBODY FOR DIFFERENTIATION OF SQUAMOUS CELL CARCINOMA ANTIGENS AND METHOD OF USE FOR SAME BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a specfic binding antibody for differentiation of squamous cell carcinoma antigen and a method for using the monoclonal antibody. Specifically, this invention relates to a urine monoclonal antibody for differentiation of a squamous cell carcinoma antigen of cytoskeletal proteins having molecular weights of 48 to 50 KD and 57 KD and a method for using the monoclonal antibody. 2. Description of the Background Art G. Kohler and C. Milstein reported a lymphocycte fusion method in their article, "Continuous Cultures of Fused Cells Secreting Antibodies of Preferred Specificity", Nature 265:495 (1975) . Their work produced monoclonal antibodies by fusing mouse myeloma tumor cells to spleen cells derived from a mouse that was previously immunized with an antigen. This discovery of antibody production provides a method for unlimited supply of pure antibodies and antibody reagents. These antibodies provide useful tools for cancer diagnosis and therapy. A multilayered epithelia is found in the epidermis, the mouth and oral cavity, the esophagus, the epiglottis, the larynx, the pharynx, the vagina, and the cervix. These are areas where squamous cell carcinoma and precursor cells of the transformation process are located. Precursor cells are squamous cells, in any stage of transformation, that are committed to become invasive squamous cell carcinomas. This "pre-SCC stage" is a stage occurring prior to cells being in "frank malignancy" or cancerous cells. The pre-SCC stage includes squamous cells which are morphologically normal, atypia (hyperplasia, metaplasia, hyperkeratosis) , significant atypia, dyεplasia (mild dysplasia - CIN 1, moderate dysplasia- CIN II, and severe dysplasia - CIN III) or carcinoma in situ (CIS) . Benign squamous cells in the pre-SCC stage are not committed to become invasive squamous cell carcinomas. Squamous cell carcinoma (SCC) is a common histological type of cancer of the head and neck, lung, oral cavity, or cervix. Identification and characterization of molecular markers associated with squamous cell carcinoma facilitates earlier diagnosis and treatment of squamous cell carcinomas. Functional studies on squamous cell carcinoma markers can aid in better understanding of the biology of this type of cancer. Monoclonal antibodies (MAbs) are useful tools as molecular and functional probes for studying tumor associated antigens. The majority of the monoclonal antibodies raised against squamous cell carcinomas are produced by using squamous cell carcinoma cell lines as the immunogen. Antigenic molecules defined by such monoclonal antibodies include cell- surface proteins and cytoskeletal components. Several monoclonal antibodies reacting with squamous cell carcinoma nave been reported. However, many of these antibodies either show cross reactivity with other types of cancers or their reactivity is limited to squamous cell carcinomas of certain organs only. Antibodies have been developed against keratinocytes and their reactivity with squamous cell carcinomas evaluated. A monoclonal antibody produced against human keratinocytes, VM- 2, has been reported to selectively bind to the basal layer of the epidermis, as well as squamous and basal cell carcinomas. This antibody is disclosed in two articles: Morhenn, et al. , "A Monoclonal Antibody Against Basal Cells of Human Epidermis: Potential Use in the Diagnosis of Cervical Neoplasis" J. Clin. Invest. , 76: 1978-1983, 1985 and Oseroff, et al., "Use of Murine Monoclonal Antibody Which Binds to Malignant Keratinocytes to Detect Tumor Cells in Microscopically Controlled Surgery" J. Am. Acad. Dermatol.. 8: 616-619, 1983. Monoclonal antibodies developed against cytokeratins have been used as probes for studying the keratin expressions in normal and neoplaεtic epithelia. Cytokeratins exhibit a differentiation-specific pattern of distribution in different layers of stratified epithelium. Specific keratin polypeptides have also been reported as molecular markers for squamous cell carcinoma. Antikeratin MAbs have been proposed as tools for diagnosis of tumors including squamous cell carcinomas. Antibodies that are known to react with squamous cell carcinoma antigens include MAbs AEl and AE3, MAb 17.13, and MAbs, PKKl and PKK2. These antibodies have been described by numerous sources including those identified below. These antibodies fail to differentiate the cytoskeletal proteins with a molecular weight of approximately 48 to 50 kD and 57 KD. The MAbs AEl and AE3 are described by: T.T. Sun, et al., J. Invest. Dermatol.. 81: 1095 (1983) ; W. G. Nelson, et al., Cancer Res. 44: 1600 (1984); Hybritech, Inc. (Hybritech) , product insert provided with MAb AEl and AE3 ; and J. Reibel, et al. , Acta Path. Microbiol. Immunol. Scand. Sect. A 93: 323 (1985) . The tissue specificity for MAb AEl is the epidermal basal layer and almost all epithelia. The tissue specificity for MAb AE3 is entire epidermis and all epithelia. MAb AEl binds squamous cell carcinoma as well as non-SCCs (e.g., adenocarcinoma) . No information is available on staining of a squamous cell carcinoma using MAb AE3 alone. MAb AEl recognizes keratins of acidic type (Mr 40, 50 and 56.5 KD) , whereas MAb AE3 recognizes keratins of basic type (58, 52 and 65-67 KD) . Hybritech claims "a combination of these two antibodies recognizes almost all known human epithelia keratins." Since these antibodies have a broad spectrum of reactivity towards keratins, they are useful for distinguishing epithelia tissues and their neoplasms from non-epithelial tissues and their neoplasms. However, neither of these antibodies can distinguish "stratified squamous epithelia" and neoplasms derived from them from other types of epithelia (e.g., simple epithelia) and tumors of other epithelia origin. The MAb 17.13 is described by R. Rankin, et al. , Cancer Res. 47 : 5684 (1987) and European Patent Application (InTek Diagnostic) Number 87311402.0. (The latter reference summarizes the characteristics of many anti-SCC antibodies.) No characterization of the antigen recognized by this antibody has been reported. The antigen is presumed to be an intermediate type filament, based on electron microscope data. The European patent application states that the antigen is not a cytokeratin. The antibody is specific for basal layer of stratified squamous epithelia. Its reactivity with precancerous lesions of CIN (Stages I-III) is approximately 30% positive. Molecular weight and other characteristics of the MAb 17.13 antigen have not been reported. The SCC-reactivity of MAb 17.13 is homogeneous. The reactivity of MAb 17.13 with animal tissues is unknown. The MABs PKKl and PKK2 are described by Holfhofer, et al., Lab. Invest. 49: 317 (1983) and product inserts of LabSystems, Inc. (Chicago, Illinois) for MAbs PKKl and PKK2. These antibodies, respectively, recognize the PKKl antigen which is a cytokeratin (Mr 41 KD, 45 KD, 48 kD and 56 kD) and the PKK2 antigen for which information is not available. MAb PKKl binds to all layers of stratified epithelia. PKK2 reportedly (according to Intek) binds to basal and parabasal layers of stratified squamous epithelia as well as columnar epithelium of the normal lung. MAb PKK2 binds to SCCs, but also binds to bronchioalveolar carcinoma. MAb PKKl binds to all layers of stratified epithelia and reacts with a broad range of cytokeratins. MAb PKK2 also shows broad reactivity in that it is reactive with normal columnar epithelium (lung) as well as stratified epithelium. Thus, it fails to distinguish stratified squamous epithelia from other types of epithelia. Besides, its tumor reactivity also lacks specificity in that it reacts with lung tumors of nonSCC type. The art lacks an antibody preparation that is specific for squamous cell carcinoma antigens in many organs and which is useful as a therapeutic and diagnostic agent. SUMMARY OF THE INVENTION The invention is an antibody preparation which essentially only recognize antigens associated with squamous cell carcinoma (SCC) and stem cell populations of stratified epithelium. Preferably, this preparation comprises monoclonal antibody MAb 174H.64 or a specific binding fragment thereof. The antigens recognized by MAb 174H.64 include cytoskeletal proteins with molecular weights of approximately 48 to 50kD and 57kD. The invention includes methods for using the antibody, including use for diagnosis of squamous cell carcinoma tumors by immunohistology, immunodetection of circulating SCC antigens in sera, non-invasive diagnostic immunoimaging .in vivo, treatment of squamous cell carcinoma tumors using antibodies conjugated to cytotoxic drugs or tagged with a radiosotope, and as a research tool for studying the normal and pathological conditions of stratified squamous epithelium. The invention includes kits wherein the antibody, antibody preparation, or a method of this invention is used. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the pattern of MAb 174H.64 binding to squamous cell carcinoma tissues. The peripheral layer of a human anorectal SCC is selectively stained by immunoperoxidase. Figure 2 compares the specificity of cell killing of the different antibodies and antibody conjugates with DM alone. Figure 3 illustrates uptake of 125 I-IUdR relative to SCC cells injected. Figure 4 shows the reduction in uptake as a result of various pretreat ents of the SCC cells. Figure 5 shows the uptake when, after injection of SCC cells into mice, the mice are treated with DM, MAb 174H.64, or a MAb 174H.64-DM conjugate. Figure 6 illustrates the effect of MAb 174H.64-DM on survival of tumor bearing mice. Figure 7 is a photograph of a scan of a patient's lung, imaging a metastasis of a cervical carcinoma by means of a MAb 174H.64-DM conjugate. DETAILED DESCRIPTION OF THE INVENTION The invention includes antibody preparations. The term "antibody preparations" encompasses whole antibodies according to this invention as well as specific binding fragments of such antibodies. An antibody or antibody fragment according to this invention can be conjugated to another substance. Such substances include labels (including, without limitation, radioisotopes, enzymes, co-enzymes, enzyme inhibitors, fluorophores and fluorescence quenchers) , cytotoxic drugs such as daunomycin, and macromolecular chromatographic supports. The antibody preparation may be monoclonal or polyclonal, but if polyclonal it is essentially monospecific for squamous cell carcinomas and stem cell populations of the squamous epithelium. Use of monoclonal antibodies is preferred. The invention includes a murine monoclonal antibody for differentiation of squamous cell carcinoma antigens and a method for using the monoclonal antibody. The monoclonal antibody of this invention selectively or, essentially, only recognizes antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium. The antibody, in well-differentiated squamous cell carcinoma tumors, preferentially binds with the peripheral proliferative compartment of the tumor. The antigens recognized by the monoclonal antibody of this invention include cytoskeletal proteins with molecular weights of approximately 48 to 50kD and 57kD. The potential applications of the antibody include diagnosis of squamous cell carcinoma tumors by immunohistology, nσninvasive diagnostic imaging jin vivo, treatment of squamous cell carcinoma tumors using monoclonal antibodies conjugates of radionuclide or cytotoxic drugs, and as a research tool in studying the normal and pathological conditions of stratified squamous epithelium. The monoclonal antibody, though raised against Tn-HSA, does not demonstrate any reactivity with this non-SCC immunogen and demonstrates a high degree of selectivity towards squamous cell carcinoma tissues. The preferred monoclonal antibody of this invention is designated MAb 174H.64. The description of this invention shall refer primarily to this preferred monoclonal antibody. The reference to the preferred embodiment of the invention in this description is not intended to exclude essentially equivalent variations of the preferred monoclonal antibody from the invention. The organ of origin can include the mouth and oral cavity, the esophagus, the epiglottis, the larynx, the pharynx, the vagina, and the cervix. MAb 174H.64 selectively binds with human squamous cell carcinoma (100% in the inventors' studies) irrespective of the organ of origin. This antibody does not bind with tumors derived from simple epithelia or tumors of non-epithelial origin. This squamous cell carcinoma-specific reactivity of the antibody extends to spontaneous SCC-like tumors of other mammals including cows, dogs and cats. No data is available for the reactivity of MAb 17.13 and VM-2 with animal tumors. MAb 174H.64 selectively binds with a stem cell population (basal and parabasal layers) of normal human stratified squamous epithelium. The antibody also shows selective reactivity with thymic epithelium and myoepithelial cells of breast ducts. The antibody does not bind with simple epithelia or non-epithelial tissues. This suggests that MAb 174H.64 recognizes a differentiation antigen characteristic of stem cell populations of stratified squamous epithelia. MAb 17.13 and VM-2 also show selective reactivity with the basal layer of stratified squamous epithelium. MAb 17.13 has also been reported to be reactive with myoepithelial cells of human breast ducts. Nσ data is available for the reactivity of these two antibodies with thymic epithelium and for the reactivity of VM-2 with myoepithelial cells. Squamous cell carcinoma tumors with high degree of differentiation show preferential binding of the antibody towards the peripheral layer of the tumor comprised of highly proliferative primitive cells. The more differentiated cells, towards the center of the tumor show little or no staining with the antibody. This observation suggests that the epitope recognized by MAb 174H.64 is characteristic of the proliferative compartment of the squamous cell carcinoma and is not expressed by the more differentiated squamous cell carcinoma tumor cells. This is surprising in that it is believed that no other monoclonal antibody has such selective reactivity towards the proliferative compartment of squamous cell carcinoma. This characteristic can provide a valuable diagnostic and therapeutic utility for the invention. MAb 174H.64 shows a unique pattern of staining with normal human cervix. The reactivity of MAb 174H.64 with basal and parabasal layers of mature squamous epithelium is 97 and 81%, respectively, whereas the reactivity is reduced to about 73 and 59%, respectively, in immature squamous epithelia. The subcolumnar (reserve) cells of the cervix show a reactivity of 70%. These results suggest that the differentiation antigen recognized by MAb 174H.64 is also a marker for epithelia maturation in the cervix. MAb 174H.64 shows binding with premalignant lesions. In cervical intraepithelial neoplasia (CIN) 69% of the cases showed reactivity with basal layer and 54% of the cases showed reactivity with parabasal layer. In kilocytotic atypia (KA) all of the cases tested showed reactivity with the antibody. The antigens recognized by MAb 174H.64 are two cytoskeletal proteins with approximate molecular weights of 48 to 50kD and 57kD. These molecular weights, although suggestive of human cytokeratins #14 and #5 which are markers for non- keratinizing stratified squamous epithelium, are different since the cytokeratins #14 and #5 are distributed also in suprabasal layers. The monoclonal antibody of this invention can be useful as a diagnostic reagent, a therapeutic agent for squamous cell carcinoma tissue, and a research tool. The highly selective reactivity of MAb 174H.64 can be used as a reagent for unambiguous diagnosis of squamous cell carcinomas irrespective of the tissue of origin. This diagnostic utility can include immunohiεtological diagnosis, diagnostic imaging, and serodiagnosiε. The therapeutic utility can include specific use as a target cytotoxic drug. The research utility can include numerous useε regarding cell studies and therapeutics. The antibody may also be used in the immunopurification of SCC-associated antigens. The purified antigenε may be uεed to raiεe monospecific monoclonal or polyclonal antibodies for use aε taught herein. MAb 174H.64 can be used as a reagent for histological typing of tumors in frozen εections. For example, the diagnoεiε of adenoεquamouε carcinoma of cervix can be difficult with reεpect to aεcertaining whether undifferentiated areaε are of;squamous or glandular derivation. A positive staining with MAb 174H.64 can resolve this problem, which may be difficult even with electron microscopy. For such diagnostic purposes, any labeling technique suitable for histological use may be employed, including but not limited to radiolabels, fluorophoreε, enzymes, and ferritin. The labeling may be direct or indirect (e.g., via an avidin-biotin, protein A-F c , or antibody -F c bridge) . MAb 174H.64 can be used for diagnostic imaging of squamous cell carcinoma. Unambiguouε diagnosis of squamous tumors based on selective jn vivo localizations of radiolabelled MAb 174H.64 can be especially valuable for the following applications. This procedure can determine that location, size, and extent of the invasion of the primary tumor. It can track the metastatic spread of the tumor and detect small metastatic areas in lymph nodes or organs, thus preventing the need for exploratory surgery. The procedure provides non-invasive determination of the histogenesis of a tumor. It can also provide a noninvasive monitoring of the response of the tumor to treatment. The localization of the monoclonal antibody in a tumor, that is necessary for use in diagnostic imaging, is demonstrated in Table 1. The acutal imaging of a tumor is set forth in Example 3. TABLE 1 Biodistribution of 125 I - 174H64 and 13 I - MOPC-21 (isotype matched control antibody) in normal and tumor bearing (KIN-205 a murine squamous cell carcinoma) lung of DBA2 mice 72h after the injection of the antibodies. % Injected % Injected dose/g tissue dose in the organ 174H.64 MOPC- ■ 21 184H.64 IOPC Tumor Bearing lung 7.7 1.6 5.4 1.16 ±0.99 ±0.51 ±2.85 ±0.97 Normal Lung 5.5 1.9 0.94 0.34 +0.209 ±1.3 +0.062 +0.24 Serodiagnosis can be performed, if the antigens detected by MAb 174H.64 are shed into serum. Detection is then possible by the ability of the serum to bind the monoclonal antibodies using ELISA, RIA or other immunoassay techniques. This principle can also be extended, as a diagnostic tool, to detection of the antigen shed into urine in bladder squamous cell carcinomas, or of antigen shed in other biological fluids as appropriate. The monoclonal antibody of this invention can provide specific therapy for squamous cell carcinoma. The monoclonal antibody in such therapy can be used alone, or to deliver a cytotoxic or radiolabelled conjugate to the target SCC cells. Studies with a dauno ycin conjugate of this antibody demonstrate the conjugate's ability to kill a murine squamous cell carcinoma cell line in a selective fashion. Tables 2 and 3 demonstrate this therapeutic utility. TABLE 2 Hematσpoietic reccristitution of lethally irradiated DBA2J mice with syngeneic bone marrow from which contaminating KLN-205 squamous cell carcinoma cells had been purged with a target-specific immunoconjugate (174H.64 - Daunσmycin) T__-eai__ment Groups cpm in Lung means + SD bone marrow only 1 1,,337/22 ±± 449y bone marrow + KLN-205 (untreated) 29,336 ± 4,505 bone marrow + KLN-205 (EM treated) 11,065 ± 6,144 bone marrow KLN-205 (antibody treated) 29,197 ± 2,490 bone marrow + KLN-205 (.Immunoconjugate treated) 4,207 ± 2,121 A mixture of 1 x IQ 6 DBA2J bone marrow cells and 1 x 10 6 KLN-205 cells was treated in vitro for 2 hours at 4°C washed and injected into each of 850 rad irradiated recipients. Twenty-five days later, lungs were tested for 125 I-IUdR inx-rporation by injecting 2 μCi of 125 I-IUdR and counting the lungs for 125 14 h after the injection. The concentration of the .Immunoconjugate was adjusted to contain lOμg/ml of EM. TABLE 3 Effect of MAb 174H.64 DaurTomycin (CM) conjugate in vivo treatment, as the KLN-205 SCC tumor growth in DRA27 mice. Number of Group Animals CTM( 1 5 I-IUdR Uptake) Normal 4 8.038 ± 3,471 174H.64 Dauncaπycin 5 32, 668 ± 20,354 Conjugate Untreated 3* 108,464 ± 82,570 * Two of the untreated mice died on day 30 of the experiment and had extensive tumor spread in the lung. * KLN-205 (10 6 cells) were injected into DBA2 male mice and were divided into two groups (5 mice each) Five of the above mice each were injected with MAb 174H.64-EM (lOOμg LM, 1.8 mg of MAb, on the 5th and the 10th days after the injection of KLN-205 cells. On the 34th day 2 μCi of ■ 25 I-IUdr was injected intravenously to each mice and lungs were taken out and counted in a gamma counter. The present invention is not limited to the use of a particular cytotoxic drug, though daunomycin is preferred . Other cytotoxic drugs known to be effective against cancer cells include ricin. Nor is it limited to any particular method of conjugating the cytotoxic drug to the antibody, though use of an acid-sensitive cis-aconityl spacer is preferred. MAb 174H.64 can be labelled with radionuclides such as 31 I, 125 I, 0 Y, 211 At, 67 Cu, and 86 e and used to deliver therapeutic doses of radiation selectively to the squamous cell carcinoma tumor tissue. For the purpose of the appended claims, reference to the antibody as being associated with a cytotoxic agent is intended to include antibodies labeled with a therapeutic radionuclide. MAb 174H.64 can be used for imaging when labelled with radionuclides such as 99 Tc, 111 In, and 67 Ga. The present invention is not limited to use of a particular radionuclide or radiolabeling technique. The monoclonal antibody of this invention can be used as a research tool as follows. Expression of the cytoskeletal proteins can be detected by MAb 174H.64 during differentiation of the normal stratified epithelium and used to establish its functional significance. Evaluation can be performed of premalignant lesions of uterine cervix such as CIN and KA. This monoclonal antibodies binds with 69% of basal CIN and all of KA tissue samples tested. Clinical and therapeutic significances of positivity and negativity can be determined by careful clinical and pathological follow up. The prognosis of the lesion can be defined in terms of negativity or grades of positivity to this antibody. The monoclonal antibody can be used to study the biology of squamous cell carcinoma with respect to expression of the antigen during transformation, progression, and differentiation of the tumor. The monoclonal antibody of this invention can be made and used according to the following example. A hybridoma cell line secreting MAb 174H.64 was deposited under the Budapest Treaty on April 18, 1989 at the American Type Culture Collection (ATCC) , Rockville, Maryland, and has received the designation ATCC HB 10105. The deposit of this cell line should not be construed as a license to recipients to use the cell line. Example 1: Preparation and Characterization of MAb 174H.64 The example is of the preferred embodiment of the invention. The preferred embodiment of the invention is the monoclonal antibody designated MAb 174H.64. The following procedure represents the best mode for deriving and testing the monoclonal antibody of this invention. The comparative data are provided for comparison purposes to demonstrate certain unexpected and desirable characteristics of the invention. Immunization and hybridoma production -RBF/Dn mice were immunized by two consecutive i.p. injections, one week apart, of a mixture of human choriogonadotrophin (HCG, 50 μg) and a synthetic carbohydrate conjugated to human serum albumin. This conjugate (Tn-HSA) is N-acetyl galactosamine alpha-linked to human serum albumin at a ratio of 40 residues per molecule of carrier (50 μg) in complete Freund-'s adjuvant. On the 12th day they were given another i.p. injection of a mixture of HCG (400 μg) and Tn-HSA (400 μg) in phosphate-buffered saline (PBS, contains 140 M NaCl, 2.6-3mM KC1, 8.1 mM Na 2 HP0 A .2H 2 0, 1.4 mM KH 2 P0 4 , pH 7.2). On 13th day they were further immunized by an i.v. and an i.p. injection, each consisting of a mixture of HCG and Tn-HSA (200 μg each) . The latter procedure was repeated on the 14th day. On the 15th day, the spleen cells from mice having high antisera titres against HCG and Tn-HSA were fused with FOX-NY cells (Hyclone Lab. , NY) . Hybrids with positive reactivity against Tn-HSA and negative reactivity with HSA were selected and recloned. The supernatants from the reclones were tested for reactivity against tumor tissues by immunohistological staining. A redone designated 174H.64 showed strong and selective reactivity with human squamous cell carcinomas, although it did not show any reactivity with Tn-HSA. This hybridoma (double recloned) was chosen for further studies based on its selective reactivity with squamous cell carcinoma tissues. Isotyping MAb 174H.64 was isotyped using a Mouse Type Isotyping Kit (Biorad Laboratories, Mississauga, Ontario, Canada) by an enzyme immunoassay (EIA) method. A microtitre plate was coated with the antibody by an overnight incubation of 4"C of the culture supernatant of the hybridoma grown in serum free medium. The microtitre wells were serially incubated with bovine serum albumin (1%) in PBS for 30 minutes at 37°C, isotyping reagent (rabbit anti mouse Ig subtypes) for two hours at room temperature, and goat anti rabbit IgG conjugated with horseradish peroxidase (HRP) for 1 hour at room temperature. After each of the above steps, the plate was washed with PBS. Finally, the microtitre wells were incubated with HRP substrate solution for 30 minutes at room temperature and the optical density read by an EIA reader. Purification of 174H.64.R24; Radiolabellinc- and Biotinylation Ascitic fluids were produced by injection of hybridoma 174H.64 cells (2 x 10 5 ) i.p. into pristane-primed Balb/c mice. The antibody was purified by a two step procedure involving ammonium sulphate (50%) precipitation and protein A sepharose column chromatography. The purified antibody fraction contained a single protein band on cellulose acetate electrophoresis and was immunoreactive on squamous cell carcinoma frozen sections as shown by immunoperoxidase staining. The antibody was radioiodinated by the iodogen method. Purified MAb 174H.64.R24 (50 μg) in phosphate buffered saline (PBS, 50 μg) was mixed with "no carrier added" Na 125 l (500 Ci) in PBS (10 μl) and was transferred into a borosilicate glass tube coated with iodogen (2 μg) at the bottom. The reaction was allowed to proceed at room temperature for 2 minutes and the solution was then transferred into another tube containing 0.05% KI in PBS (100/μl) and allowed to equilibrate for 3 minutes the antibody was separated from inorganic iodide using a Biogel P-100 spun column. MAb 174H.64 was biotinylated according to a known, reported procedure. A solution of MAb 174H.64 (2 mg) in PBS (400 μl) was mixed with 0.2 M sodium bicarbonate solution containing 0.15 M potassium chloride pH 8.1. To this a solution of Biotin-LC-NHS (125 μg, Pierce) in PBS (25 μl) was added and incubated at room temperature for 20 minutes. The reaction was stopped by addition of 1 M ammonium chloride solution pH 6.0 (50 μg) and the solution was extensively dialyzed against PBS. Cell Lines All the squamous cell carcinoma cell lines were obtained from American Type Culture Collection, Rockville, Maryland, and grown in RPMI containing 10% fetal calf serum (FCS) and gentamicin (40 units/ml) . Normal human keratinocytes were obtained from Clonetics Corporation, San Diego, CA, and were cultured in serum free keratinocyte growth medium (Clonetics Corporation) . Isolation of mouse epidermal keratinocytes Epidermal keratinocytes were isolated from neonatal (1 day old) ICR mice according to a known, reported procedure. Briefly, mice were decapitated, skin was removed and washed in Hanks balanced salt solution (HBSS) . The skin was then placed dermal side down in HBSS containing trypsin (0.025%) EDTA (0.02%) and incubated at 37°C for 1 hour. The trypsin EDTA solution was aspirated and replaced with RPMI with 10% FCS. The epidermis was then gently separated from the dermis using forceps and agitated gently in the medium. The resulting cell suspension was then separated from the epidermal and dermal layers and washed 2 times with RPMI followed by PBS. This cell suspension was used for immunoperoxidase staining. Immunohistology Tumor tissues for immunohistological studies were embedded in OCT, frozen in isopentane and stored at 70°C. Immunoperoxidase staining of frozen sections or cell smears were done according to the avidin-biotin peroxidase complex (ABC) method that is known in the art. Frozen sections of 8 um were cut on a cryostat and mounted on poly L-lysine (PLL) coated glass slides. The cell smears were prepared from a single cell suspension of cells using PLL coated glass plates and were air dried. The glass slides were then serially incubated with primary antibody (174H.64) for 15 minutes, with 0.02% glutaraldehyde for 5 minutes at 4°C, with biotinylated secondary antibody (antimouεe IgG) for 30 minutes, and with ABC reagent for 20 minutes. After each of the above stepε, the slides solution containing 0.5% hydrogen peroxide for 5 minutes, washed in water, counterstained with hematoxylin and mounted in permount. A brown color in the cells corresponds to positive reaction with the antibody. Whenever mouse tissueε were εtained by the above procedure, a biotinylated primary antibody was used and the εtep with the antimouse IgG was omitted. An iεotype matched mouse myeloma protein (MOPC-21) was used as a negative control antibody in all immunoperoxidase staining. Reactivity of MAb 174H.64 With Cancer Tiεsues Frozen εectionε of human cancer tissues of various origins were teεted for reactivity with MAb 174H.64 by immunoperoxidaεe staining by the ABC method. An isotype matched control antibody (MOPC-21) waε uεed aε a negative control. The reεultε of these studieε are εummarized in Table 4. TABLE 4 The binding of MAb 174H.64 with frozen εections of human tumors of various origins. Tumor Number Teεted ISIumber Positive Sqjαamσus cell Carcinoma Lung 36 36 Skin 9 9 Tongue 1 1 Uterine Cervix 4 4 Naεopharynx 2 2 Larynx 3 3 Penis 1 1 Vulva 2 2 Anuε 2 2 Lip ' 2 2 Nαn-Squamouε Lung Carcinomaε (Adeno, Small Cell and Large Cell) Adeno Carcinoma Breast 3 10 0 Colon 7 0 Ovary 15 0 Proεtate 1 0 TABLE 4 (Continued) The binding of MAb 174H.64 with frozen sections of human tumorε of variouε originε. Tumor Number Teεted Number Positive Non Salivary Gland Biphaεic Malignancies with Squamous Component Adenocarcinσmata with Admixed Mature Squamous Component, "Adenoacanthoma" of Endometrium 3(εquamouε Component only) Adenocarcinoma with Malignant Squamouε Component, Adeno- εquamouε Carcinoma of Pancreaε 1(εquamouε Component only) Carcinoεarcσma with Squamous Epithelial Component, Pulmonary Carcinoεarco a 1 1(εquamouε Component only) Biphaεic Malignancieε of Salivary Glandε Mucoepidermoid Carcinoma 1 1(Component of Squamoid cellε that are of myoepith¬ elial origin) Adenoid Cyεtic Carcinoma l(Cell populations, often about "pseudo- cysts," believed to be of myo¬ epithelial origin and having some squamous features by electron- microscopy) TABLE 4 (Continued) The binding of MAb 174H.64 with frozen εections of human tumorε of variouε origins. Tumor Number Teεted Number Poεitive Tranεitional Cell C-arcinαma Bladder 1 Benign Tumors Ovary 10 0 Breast 5 0 Squamous Mucoεa 2 2(basal cell only Melanocytic Nevi 6 0 Salivary Tumourε 3 3(Biphasic - only myo¬ epithelial cellε stained) Thymαma 1(Epithelial Component only) Other Carcincmaε Kidney - 2 Lymphαmaε B Cell Lymphσma 10 0 Hodgki ε 2 0 Sarcσmaε Miεcellaneσuε Soft Tiεεueε 4 Melanomaε Cutaneouε 5 The myopithelial cellε of breast ducts were positive. MAb 174H.64 εhowed εelective binding with all human squamous cell carcinomas tested irrespective of the organ or origin, for a variety of other hiεtological type of tumorε. Figure 1 showε the pattern of MAb 174H.64 binding to εquamouε cell carcinoma tissues with preferential binding of the antibody to the peripheral layer of the tumor. The normal tisεueε adjacent to the tumor εhowed no binding with the antibody. Several spontaneously arising tumors from other mammals were also studied for their reactivity againεt MAb 174H.64 and the resultε are εummarized in Table 5. TABLE 5 The binding of MAb 174H.64 with frozen section sof non-human tumorε. Tumor Number Tested Number Positive Canine Tumors Squamouε/Baεal Cell Carcinomas 10 10 Other carcinomas 14 0 Benign basal cell tumors 4 4 TABLE 4 (Continued) The binding of MAb 174H.64 with frozen sections of human tumors of various origins. Tumor Number Tested Number Positive Canine Tumorε (cont'd) Papillomaε 3 4 4 Perianal adenoma 3 2 2 Other benign epithelia tumors 5 0 Mesenchymal tumors 45 0 Bovine Squamous Cell Carcinoma 4 4 Feline Squamous Cell Carcinoma 2 2 a In papillomaε and perianal adenomaε only the baεal cell population showed εtaining with the antibody. Canine squamous and basal cell carcinoma tissues showed selective binding with the antibody while other carcinomas and tumorε of meεenchymal origin did not show any reactivity. The reactivity of the antibody was also observed for bovine and feline squamous cell carcinomas . In the staining of a well-differentiated metastitic bovine lung squamouε cell carcinoma , we obεerved increased antibody binding to the peripheral tumor cellε . Among the benign epithelia tumors of dogs , basal cell tumors showed homogeneous εtaining, whereaε in papillomas and perianal adenomas , the staining was limited to basal cellε only . Reactivity of MAb 174H . 64 With Normal Tissueε Normal human tiεεueε were εtudied for their reactivity with MAB 174 . 64 and the results are summarized in Table 6. Highly selective reactivity was observed for the basal cells of the stratified epithelium, thymic epithelium, and myoepithelial cells around breast ducts . No reactivity waε observed for non-εtratif ied epithelium (e . g . , colon) or tissues of non-epithelial origin . TABLE 6 The binding of MAb 174H.64 with frozen sections of normal human tissues. Tissue Number Tested Number Positive Cells Staining (primarily Cell Cyto¬ plasm Positivity un- leεε Indicated Other- wiεe) Colonic mucosa 6 0 Heart 1 0 Liver 3 0 Ovary 7 0 Fallopian Tube 2 0 Breast 14 14 Duct myoepithelial cellε only Er_dαmetrium 10 0 a-_docervix 25 0 Subcolu nar cellε in continuity with basal cells can be positive under special ci__ * cumstances Connective Tissueε 40 0 Skeletal Muscle 3 0 Ωiyroid 4 0 Parathyroidε 1 0 TABLE 6 (Continued) The binding of MAb 174H.64 with frozen sections of normal human tissues. Tissue Number Tested Number Positive Cells Staining (primarily Cell Cyto¬ plasm Positivity un- leεε Indicated Other- wiεe) Epidermiε 5 5 (Basal and parabasal cells b** Exocervix 25 25 Baεal and parabasal cells b** Other Squamous Mucosa 15 15 Basal and parabasal cellε Reεpiratory ucoεa includliinngg Bronchial mucosa 15 0 Other Lung Tiεsues 12 0 Transitional Epithelium 5 0 TABLE 6 (Continued) The binding of MAb 174H.64 with frozen sections of normal human tissues. Tissue Number Teεted Number Positive Cells Staining (primarily Cell Cyto¬ plasm Positivity un¬ less Indicated Other¬ wise) Kidney 4 0 Brain 3 0 Prostate 2 0 Pancreas 2 2 Duct myoepithelial cellε Salivary Glands Duct and lobular myoepithelial cells Thymus 3 3 Thymic epithelial cells with prominent filaments extending along outer rim of thymic cortex and within central thymic medullary regions a* a* The only normal human cell with εignificant cell membrane accentuation on 174H64 i munoεtaining, and εignificant accentuation of greatly elongated cell proceεses iε the thymic epithelial cell. b** In inflammation of squamous epithelium, significant cell membrane accentuation on 174H64 ilmmunoεtaining, and significant accentuation of elongated cell filamentous proceεεeε, is seen on isolated scattered intraepithelial anucleate dendritic cells, presumably of keratinocyte origin. In addition, extracellular pools containing 174H64 filamentous deposits, located between viable nonreactive keratinocytes, are found in inflamed, especially virally inf lammed, squamouε epithelium. The reactivity of the antibody with the basal layer of the εtratified epithelium waε alεo demonεtrated on bovine and mouεe εkin . A mouεe keratinocyte εuεpenεion enriched in baεal cellε waε prepared by trypεin dissociation of the neonatal mouεe εkin . A cell εmear of thiε εuεpenεion on immunoperoxidaεe εtaining εhowed 30 to 50% of the cellε to be poεitive for their reactivity with the antibody . A normal human keratinoyte culture having baεal cell characteriεticε demonεtrated all cells to be positive for their reactivity with the antibody . Reactivity of MAb 174H . 64 With SCC Cell Lines While as previously stated , MAb 174H . 64 was reactive with all SCC tissue sections tested , several human squamous cell carcinoma cell lines (SCL-1 , SIHAA, ME 180 , C-33A) were tested for their reactivity with the antibody by cell smear immunoperoxidase staining and were found negative . In contrast , a murine metastatic lung squamouε cell carcinoma cell line (KLN-205.} " , &.aε reactive with the antibody . Reactivity " ~Qf MAb 174H . 64 with Squamous Cell Carcinoma Animal Model KLN-205 cellε ( 10 6 ) were inj ected i .v . into 8 week old DBA/2 male mice by a method εtandard in the art . The lungε , diεεected from theεe mice after 21 days , showed extensive tumor colony formation . This tumor on immunoperoxidase staining showed εtrong reactivity with the " antibody and preferential staining of the cells in the S periphery of the tumor. Adjacent normal tisεueε as well as the lung tisεue from a normal mouεe did not εhow any binding with the antibody. Characteristics of the antigen Protein extractε were prepared from a bovine metaεtatic lung εquamous cell carcinoma tumor, a human lung squamous cell carcinoma tumor, a human ovarian adenocarcinoma tumor, and normal human epidermal keratinocytes grown in vitro as follows. The tiεεue samples or cell pellets were homogenized with 10 volumes of a Nonidet P-40 (NP-40, Sigma Chemical Company) extraction buffer (1% NP-40, 2 mM EDTA, 1 mM penyl methyl sulphonyl fluoride, 2 mM pepstatin 10 mM o- phenanthrolin, and 150 mM NaCl in 50 mM Triε HCl buffer pH 7.5) at 4°C for 30 minutes and then centrifuged at 100,000g for 1 hour. The residue waε again extracted uεing 10 volumes of sodium dodecyl sulfate (SDS) extraction buffer (2% SDS and 10 mM 2mercaptoethanol in 10 mM Tris HCl buffer pH 7.5) at room temperature for 10 minutes, boiled at 100°C for 10 minutes, and then centrifuged at I0,000g for 15 minutes. The proteins in these extracts were separated on a diεcontinuouε gradient SDS- poly acrylamide gel electrophoreεiε (4% stacking gel and a 4% to 15% gradient reεolving gel) under εtandard reducing conditions. After electrophoresis, the gel waε incubated in 200 mL of protein refolding buffer (4 M urea, 2 mM EDTA, 50 mM NaCl, 0.1 M dithiothreitol in Tris HCl pH 7.5) for 18 hours with one change of buffer at room temperature and then equilibrated in transfer buffer (190 mM glycine in 25 mM Tris HCl pH 8.8) at 4°C for 1 hour. The proteins were electrophoretically transferred from the gel to a nitrocellulose membrane (Biorad) at 180 mA at constant current for 18 hours. The nitrocellulose sheets were removed, incubated in the blocking buffer containing 3% gelatin in PBS for 1 hour and washed twice in TPBS (PBS containing 0.05% Tween 20) for 5 minutes. They were then incubated with 125 I labelled antibodieε (5 x 10 5 cpm/mL) in antibody buffer (TPBS containing 1% gelatin) for 2 hourε and waεhed 6 times in TPBS for 5 minutes each. The nitrocellulose sheetε were air dried and expoεed to Xray film at -70°C. The immunoblots of the NP- 40 extracts of the above tisεues and the SDS extracts of adenocarcinoma showed no binding with 125 1 labelled MAb 174H.64, while the immunoblots of the SDS extracts of bovine squamous cell carcinoma, human squamouε cell carcinoma and human keratinocyteε εhowed εelective binding of 125 I labelled MAb 174H.64 with εpecific protein bands. The immunoreactive protein bands in the keratinocyte SDS extract were of approximate molecular weight of 48 to 50kD (posεibly a doublet) and 57kD. The bovine and human εquamouε cell carcinoma SDS extractε showed only one prominent band each with the approximate molecular weight of 48 to 50kD for the former and 57kD for the latter. A control antibody (155H.7) failed to bind with any of the above tumor extractε. Reactivity of MAb 174H.64 with normal and premalignant epithelium of cervix Frozen sections of normal and premalignant epithelium of cervix were examined for binding with MAb 174H.64. The resultε are εummarized in Tables 7 and Table 8. TABLE 7 Reactivity of MAB 174H.64 with normal epithelium of cervix. Epithelium No positive/no tested % positive Mature stratified epithelium Basal layer 36/37 97.3 Parabasal layer 30/37 81.1 .Immature stratified epithelium Basal layer 51/70 72.9 Parabasal layer 41/70 58.5 Subcolumnar epithelium 8/16 50 TABLE 8 Reactivity of MAb 174H.64 with premalignant lesions of cervix. Preneσplastic lesion No positive/no tested % positive Cervical Intrapithelial neoplasia (CIN) Basal layer 36/52 69.2 Parabasal layer 28/52 53.9 Koilocytotic atypia 16/16 100 In mature and immature squamouε epithelium of the normal cervix, the staining was limited to basal and parabasal layers only. In the mature epithelium virtually 100% of the baεal and parabaεal layerε were εtained whereas in the immature epithelium the εtaining waε limited to a range between 71 and 73%. In the subcolumnar epithelium in 70% of the caseε εtaining could be obεerved for the reεerve cellε. These reεultε suggest that the expresεion of thiε antigen is acquired during the process of maturation of the epithelium and is lost while the stem cells of the mature epithelium undergoes differentiation. The staining pattern of the reserve cells can reflect the proportion of cases where reserve cells are committed to become the stem cells of the stratified epithelium. Example 2: Im unotherapeutic Uεe of MAb 174H.64 MAb 174H.64, which εelectively recognizeε an epitope expreεεed on the proliferating cellε of mammalian εquamouε carcinomaε (Sq Ca) , waε covalently coupled to daunomycin (DM) by an acid sensitive linker and tested for its εelective cytotoxicity for Sq Ca. A murine lung Sq Ca model for chemoimmunotherapy uεing MAb 174H.64-DM conjugateε waε developed. Thiε model utilizes the KLN-205 Sq Ca cell line which metaεtaεizeε to the lungε following i.v. injection and εhows a pattern of growth εimilar to thoεe of εpontaneouε Sq Ca, that is, characterized by highly proliferative cells at the periphery of the tumor (reactive with 174H.64) with the keratinized differentiated cells toward the center (not reactive with 174H.64). MAb 174H.64-DM conjugateε showed marked and εpecific cytotoxicity againεt KLN-205 cells both in vitro and following i.v. injection of the immunoconjugate in mice with establiεhed lung metaεtaεes. The conjugate was nearly as effective as DM alone when incubated in vitro with KLN-205 cellε and much more effective in vivo than DM alone. Control immunoconjugateε were ineffective. Finally, while the free 174H..64 MAb produced a εignificant increased time of survival of mice bearing KLN-205 metaεtaεeε, a much greater survival was found with mice treated with the 174H.64-DM immunoconjugate with εo e mice apparently demonεtrating long term εurvival (>100 dayε) . We conclude that MAb 174H.64 may have potential therapeutic benefit againεt Sq Ca. Materialε and Methodε Experimental animalε: DBA/2 male mice, 8-12 weeks of age, were obtained from the Medical Sciences Animal Centre, University of Alberta. Cell lines: A murine Sq Ca line, KLN-205 (Kaneko, et al., 1978) , a murine leukemia cell line, SL2R5, Wolcsin, et al., Int. J. Cancer, 23:519 (1979), and a human myeloid leukemia line, HL60-2, Gallagher, et al., Blood, 54:713 (1979), were obtained from the American Type Culture Collection, Rockville, MD. All cell lineε were maintained in RPMI 1640 medium εupplemented with 10% FCS. KLN-205 iε a murine lung Sq Ca cell line which metastasizes to the lung following i.v. injection. Kaneko, et al., Cancer Reε., 28:2084 (1978). The reεulting lung metaεtaεeε reacted with MAb 174H.64, demonεtrating εelective reactivity with the growing cells in the periphery of each tumor. Samuel, et al. , Cancer Reε., 49:2465 (1989), Williamε, et al. , J. Nat. Cane. Inεt. 51:1513 (1973) . Preparation of im unoconjugateε: Immunoconjugateε have been made in which the cytotoxic component waε daunomycin (DM) attached to the target-εpecific conjugand via the acid-εenεitive ciε-aconityl spacer (CA) . Shen, et al., Biochem. Biophys. Reε. Co m. , 102:1048 (1981). Theεe daunomycin immunoconjugateε εhowed high specific cytotoxicity on target cells and could be used for purging tumor cells and functional T cellε from bone marrow. The preεent εtudy was deεigned to teεt the potential of MAb 174H.64-daunomycin immunoconjugates to target therapy to KLN-205 Sq Ca lung tumors. Immunoconjugates were prepared as deεcribed, Diener, et al., in Antibody-Mediated Delivery Syεtem, p. 1 (Marcel Dekker, Inc., N.Y. 1988) and Xie, et al., Tranεplantation, 44:770 (1987) , according to the method of Shen, et al. (1981) . MAbε were obtained from aεcites fluids which were subjected to protein precipitation with 40% (NH 4 ) 2 S0 4 followed by dialysis against phosphate buffered εaline at 4°C for 24 hours. This protein fraction was further purified by affinity chromatography on a protein A-sepharose column (Pharmacia) . Daunomycin and cis-aconitic anhydride were purchased from Sigma Chemical Co., St. Louis, MO. Purified monoclonal antibody 174H.64 was obtained as described above. MAb anti-Thyl.2 waε obtained from NEN and MAb 86H.1 which reacts againεt human myeloid cellε, See Janowεka-Wieczorek, et al. , in Leukocyte Typing II, Vol. 3, Human Myeloid and Hematopoietic Cellε, p. 171 (Springer Verlag, N.Y. 1986) , including HL-60 cellε, waε made in our laboratorieε. Treatment of cellε with cytotoxic immunoconjugateε or other agentε: Cellε in phoεphate-buffered εaline (PBS) were treated with the immunoconjugateε or other agents for 2 1/2 hours on ice. Thereafter the cells were washed 3 times and injected intravenously into recipient mice, or incubated for 24 hours at 37°C after which 3 H-thymidine incorporation by the cells was measured. 3 H-thymidine incorporation: Cell cultures were pulsed for four hourε with 0.5 μCi/well of 3 H-thymidine (specific activity 2.0 μCi/mmol) (NEN) . Cells were harvested onto glasε fibers with a Titertek semi-automated multiple sample collector (Flow Laboratorieε, Mississauga, Ontario) . Thymidine incorporation waε determined by liquid scintillation spectrometry. Squamous carcinoma animal model: Aε described previously (Samuel, et al. , 1989) using KLN-205 cellε (Kaneko, et al. , 1978) . 125 I-IUDR uptake: Mice were injected with 2 μCi/each of 125 I-IUDR (Edmonton Radiopharmaceutical Centre, Edmonton, Alberta, Canada) and 4 hourε later, the lungε were removed, cut into εmall pieceε, waεhed with 10% trichloroacetic acid (TCA) 3 timeε for three dayε and aεsesεed for radioactivity content uεing a gamma-counter. Statistical analysis: Most data were aεsessed by Student's t-teεt. Survival data were asseεεed by modified Wilcoxon. Results Inhibition of in vitro proliferation of KLN-205 cells by MAb 174H.64-DM: We have previouεly described the selective reactivity of MAb 174H.64 with all mammalian Sq Ca teεted including the KLN-205 murine lung εquamous carcinoma cell line (Samuel, et al . , 1989). To investigate the specific cytotoxicity of the immunoconjugate, the KLN-205 cell line, SL2R5 cell line and HL60-2 cell line were treated on ice for 2 hours with MAb 174H.64-DM, MAb 86H.1-DM, MAb anti Thyl.2-DM, free DM, MAb 174H.64, MAb anti-Thyl.2 or MAb 86H.1, and following washing, the cells were subsequently cultured for another 24 hours. Fig. 2 demonstrates the specificity of cell killing of the different antibodies in comparison with the daunomycin alone. While the HL-60 cells and SL2R5 cells were each inhibited by their respective MAbs, only KLN-205 cellε were inhibited by the MAb 174H.64-DM immunoconjugate. It iε noteworthy that the inhibition in vitro of the proliferation of KLN-205 cellε by the MAb 174H.64-DM immunoconjugate waε nearly aε effective aε the daunomycin alone. In vitro treatment of KLN-205 cellε with MAb 174H.64- DM inhibitε tumor cell proliferation in the lungs of i.v. injected mice: For this experiment we employed the 1 5 I-IUDR uptake assay aε a measure of KLN-205 tumor cell proliferation in the lungε. We first eεtabliεhed that the uptake of 125 i- IUDR in the lungε iε directly proportional to the number of i.v. injected KLN-205 cellε at leaεt over the range of 10 5 to 10 6 cellε (Fig. 3) . KLN-205 cells were then treated on ice for 2 hours with the MAb 174H.64-DM immunoconjugate or with various controls, including PBS, MAb 174H.64 alone or free DM. Thereafter cells were washed three timeε and injected into DBA/2 mice (10 6 cells/mouse) . On the 23rd day after injection, tumor growth in the lung waε monitored using 125 I-IUDR uptake. Results in Fig. 4 show that the MAb 174H.64-DM pretreatment significantly reduced the growth of lung tumors approximately 85% and was as effective aε incubation of the cellε with DM alone (Fig. 4) . I.V. injected MAb 174H.64-DM inhibitε the growth of established lung metastatic KLN-205 cellε in vivo: The purpose of thiε experiment waε to investigate the specific cytotoxicity of MAb 174H.64-DM in vivo. 10 6 KLN-205 cells were injected i.v. into DBA/2 mice. Three days later MAb 174H.64-DM waε injected i.v. every εecond day for 10 dayε (5 injectionε) . On the 23rd day after injection of the tumor cells, tumor growth was measured by aεεeεεing 125 I-IUDR uptake in the lungε. The results in Fig. 5 show that MAb 174H.64-DM significantly (p<0.001) reduced 1 - I-IUDR uptake by about 80% while MAb 86H.1-DM had no εignificant effect. Daunomycin alone had a εlight, but inεignificant effect but MAb 174H.64 alone reduced the tumor cell proliferation approximately 42% (P<0.001) . Survival of mice receiving MAb 174H.64-DM Therapy: The above experiment waε repeated but inεtead of sacrificing the mice to monitor the growth of KLN-205 cellε in the lungs, the mice were simply monitored for survival. The reεultε in Fig. 2 εhow that MAb 174H.64-DM treated mice εurvived εignificantly longer (p<0.001) than untreated or antibody treated mice. MAb 174H.64 alone alεo improved the survival of tumor bearing mice (P<0.001). Discussion The present study was deεigned to teεt the hypotheεiε that a MAb directed againεt the proliferative (STEM) cell compartment of εquamouε carcinomaε haε therapeutic potential. We have uεed a novel MAb, 174H.64 which appearε to detect a unique epitope on cytoskeletal proteins which may serve aε a marker for the εtem cell population in normal εtratified squamous epithelia and squamouε carcinomas (Samuel, et al., 1981). MAb 174H.64 reacts with all Sq Ca tested regardleεε of histological origin (Idem.) aε well aε with all Sq Ca of all mammals tested, including those of humanε (>62 tested) , dogs (10 tested) , cattle (40 tested) and cats (2 teεted) . In the present εtudy we took advantage of itε reactivity with a murine metaεtatic lung Sq Ca, KLN-205, to develop an animal model for chemoimmunotherapy with a daunomycin conjugate of MAb 174H.64 (MAb 174H.64-DM). Previouε εtudieε uεing the KLN-205 cell line have εhown that the tumor periphery of the lung metastatic noduleε iε composed of highly proliferative cells which are the progenitors of the more differentiated cellε in the central portion of the tumor. We have εhown that MAb 174H.64 εelectively εtains the peripheral layer of KLN-205 lung tumorε aε well aε human and bovine Sq Ca. This provided the rationale for using the KLN-205 model to attempt to selectively target therapy to the "εte " cells of the tumor as it might be expected that the internal, more differentiated cellε are no longer capable of neoplaεtic proliferation. We chose daunomycin aε the cytotoxic component of the immunoconjugate because of our extenεive experience with this drug. Diener, et al., Science, 231:148 (1986); Diener, et al., in Cellular Basis of Immune Modulation, p. 509 (Alan R. Liss, Inc., NY 1988); Diener, et al. (1988) (Marcel Dekker) ; Xie, et al. (1987). We have previously shown that an immunoconjugate of anti-Thyl.2 MAb and daunomycin possesses high specific cytotoxicity for target cells and could be used for the specific purging of Thyl.2+ tumor cells and murine functional T cellε from the bone marrow. We have diεcovered that an immunocon ugate of MAb 174H.64 with daunomycin also produces marked, εpecific inhibition of the growth of KLN-205 murine squamous carcinoma both in vitro and in vivo when compared to irrelevant conjugates, free monoclonal antibodies, or free daunomycin. Our first experiments were designed to demonstrate the specificity of the immunoconjugate killing in vitro. For this we conducted a criεε-croεε experiment with three cell lines and three immunoconjugates which, based on i munofluorescent and/or immunoenzyme testing should be εpecific for their εpecific cell lines. Exquisite specificity and excellent killing was noted in each case: MAb86H.l-DM killed only HL-60 cellε, MAb anti-Thyl.2-DM killed only SL2-R5 cells and MAb 174H.64 killed only KLN-205 cells. Interestingly, the killing of KLN-205 cellε by the 174H.64 immunoconjugate was nearly as effective as the free daunomycin added to the culture. An extension of the in vitro experiment was then performed whereby the KLN-205 cells were incubated in vitro with the immunoconjugate, free antibody or daunomycin, washed, injected i.v., and the metastatic growth in the lungs monitored. In this case a marked reduction of the metaεtatic growth of the KLN-205 cellε in the lungε waε achieved by preincubation with the MAb 174H.64-DM conjugate. Again the reduction achieved with the immunoconjugate waε about the same as that achieved with free daunomycin. In vitro incubation with the unconjugated MAb 174H.64 caused a slight but statistically non-εignificant reduction in growth of KLN-205 cells in the lungε. The next two experiments were designed to directly test the jLn vivo therapeutic potential of the MAb-174H.64-DM immunoconjugate. Immunotherapy was started three days following the i.v. injection of 10 6 KLN-205 cells, at a time when the lung metastatic cells should have been well establiεhed (Kaneko, et al., 1981; Williamε, et al. , 1973). Five therapeutic injections of MAb-174H.64-DM were given i.v. every second day for ten days. Growth of the KLN-205 cells in the lungs waε monitored at day 23 by uεing the 125 I-IUDR uptake asεay and εurvival waε monitored for >100 dayε. The two eεtimateε of the therapeutic potential of the variouε compoundε gave very εimilar reεultε. Mice injected with MAb 86H.1-DM showed no therapeutic benefit and showed similar tumor growth and survival aε thoεe injected with PBS. Daunomycin alone gave a slight reduction of growth and a εlight increaεe in εurvival. An even greater therapeutic benefit was achieved with unconjugated MAb 174H.64. However by far the best therapy was achieved following i.v. injection with the MAb 174H.64-DM immunoconjugate where an >80% reduction in tumor cell growth in the lungs and a prolonged survival was achieved. Greatly prolonged survival was achieved in 20% (5 mice) of the mice which survived >100 dayε. The therapeutic benefit of the 174H.64 immunoconjugate iε even more impressive if one considerε that the therapeutic regimen uεed in the preεent experimentε may not be an optimal one. The efficacy of MAb 174H.64-DM probably depends on the specificity of its binding to the target cell surface and the accumulation of the drug inside the target cells. Broxterman, et al. , Biochem. Pharmacol., 37:2389 (1988); Dillman, et al. , Cancer Res., 48:6097 (1988) ; Pimm, et al., Cancer Immunol. I munother. , 27:267 (1988). Pimm and coworkers have studied human tumors growing in nude mice injected with daunomycin immunoconjugates. They found that the tumorε εhowed localization of both the drug and antibody and at the time of analyεiε (3 dayε after injection) , the tumor levels of daunomycin were over 100 times those seen in mice injected with free daunomycin. Following endocytosiε of the immunoconjugate, the potentially cytotoxic component appearε to regain full pharmacologic activity upon releaεe from the acid-sensitive spacer in lysoso es (Dillman, et al. 1988) . Those results are consistent with our observationε that at the εame daunomycin concentration the immunoconjugate MAb 174H.64-DM showed a marked suppression of the growth of KLN-205 cells in vivo while free daunomycin did not, although the free daunomycin εhowed the εame or better cytotoxic potency aε the immunoconjugate following in vitro incubation. Gallego, et al. (1984) inveεtigated four different linkage groups for coupling daunomycin to antibody. They found that conjugateε made with a ciε-aconityl linkage, which was the εame one uεed in the preεent work, displayed the greatest selective cytotoxicity against tumor cells. Our results appear to substantiate the efficacy of daunomycin immunoconjugate made with cis-aconityl linkage groups. MAb 174H.64 appearε to detect a novel epitope expreεεed on certain cytoεkeletal proteins expressed only in the stem cell populationε of normal and neoplaεtic εtratified squamous epithelium. The present experiments as well as our previous observations suggest that the epitope detected by MAb 174H.64 iε alεo expreεεed on the surface of the KLN-205 cells. Other cell εurface determinantε have been reported for εome cytoεkeletal proteins, see Diaz, et al., J. Invest. Dermatol., 89:287 (1987) ; Zimmerman, et al., J. Cell. Biol., 95:237a (1982) . As the 174H.64 epitope may alεo be preεent on the surface of the basal cellε of εtratified εquamous epithelium some εkin toxicity might have been expected in the preεent experiments. However, we have never εeen any evidence of any skin leεionε nor any other obviouε groεε pathology in over 100 mice which have received multiple injectionε of either the free 174H.64 MAb or the MAb 174H.64-DM conjugate including our long term (>100 day) survivors. Based on our studieε in mice we conclude that MAb 174H.64 may have promising therapeutic potential in Patients with squamous cell carcinoma. In our preliminary radioimmunoimaging studieε with radiolabeled MAb 174H.64 excellent j_n vivo localization of thiε MAb in human εquamouε cancer waε observed. Example 3: Immunσimaging Using MAb 174H.64 Clinical Utility of MAb 174H.64 To test the clinical usefulness of radiolabeled MAb 174H.64 as an in vivo tumor localizing agent the purified whole antibody was labeled with Technetium-99m and injected in a number of patients bearing squamous cell carcinomas. The labeling procedure was as follows: A mixture of Sodium Potassium Tartarate (0.282 g) and Potassium Phthalate (0.817 g) was dissolved in 100 ml sterile water for injection in a pyrogen-free beaker with constant stirring (the "buffer εolution") . The solution was purged with dry, particle-free nitrogen for 30 min. The nitrogen source was previouεly paεεed through a nitrogen purifier to remove trace amountε of oxygen and then filtered through a 0.02μ filter to remove any reεidual particulate contaminantε. A stannouε chloride εolution waε then prepared by dissolving 1.896 g of anhydrouε εtannouε chloride in 20 ml of concentrated hydrochloric acid to make a 0.5M SnCl 2 εolution. One milliliter of the εtannouε solution was added immediately to the previously prepared buffer solution and the pH of this final mixture was adjusted carefully to 5.6+ 0.05 with 10 N sodium hydroxide εolution. The mixture was purged with nitrogen gas and filtered through a 0.22μ filter. This is called the reducing solution. One milliliter of MAb 174H.64 solution in phosphate buffer was then mixed with 0.67 ml of filtered reducing solution and the final MAb concentration was adjusted such that the mixture contained 1 mg antibody/ml. After mixing, the vial containing the antibody and reducing solution waε purged with nitrogen for several minutes and kept under a nitrogen atmoεphere at room temperature for 21 hourε. After the incubation period, the treated antibody solution was filtered through a 0.22μ filter. The latter filtrate was assayed for its protein content, for pyrogens, for purity (using size exclusion column chromatography) and for im unoreactivity. No differences were observed between the original untreated whole antibody and the derivatized one either in terms of immunoreactivity or molecular weight. The solution of prepared antibody was then frozen until ready for use clinically. At the time of use, the vial containing the frozen reduced antibody is thawed at room temperature and the required amount of τc- 99m sodium pertechnectate solution (up to 50 mCi) were added and the mixture allowed to incubate for 1 hour at room temperature. At the end of the incubation period, a sample of the mixture was teεted for any unbound τc- 99m by thick layer chromatography uεing acetone aε a developing solvent. Radiolabeling efficiency was greater than 95%. Clinical Results A clinical study involving 11 patients with metastatic εquamouε cell carcinoma of the head and neck, cervix, and lung waε conducted to evaluate the uptake of ""Tc- labeled MAb 174H.64 after intravenouε injection into theεe patientε. An antibody doεe of 2 mg (about 50 mCi) was diluted with 100 ml normal saline and infused over 30 minutes. Any abnormal uptake was measured by planar and single photon emission computerized tomography at various intervals after the injection. Results obtained within 24 hourε indicated that two patientε εhowed an apparent negative uptake while 9 patientε were εhown to be truly poεitive. Figure 7 illuεtrateε εuch a scan observed for a patient with cervical squamouε cell carcinoma whoεe tumor had metaεtaεized to the upper cheεt region. It demonεtrateε the uptake of the antibody in a leεion estimated at 2-4 mm in diameter (εee Fig. 7) We found it to be unuεual that the pharmacokineticε of a labeled whole antibody iε indeed similar to the known behaviour of a fragment. Blood clearance was expeditious and uptake could be seen as early aε 3 hourε after injection. Analyεiε of the radioactivity in the patient'ε urine haε demonεtrated that the εecreted radioactivity waε not due to free pertechnectate, but rather due to bound radioactivity.

Claims: CLAIMS 1. A antibody preparation comprising an antibody which essentially only binds to antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium. 2. The antibody preparation of claim 1 wherein εaid antigens include cytoεkeletal proteins having molecular weights of approximately 48 to 50kD and 57kD. 3. The antibody preparation of claim 1 wherein squamous cell carcinoma specific reactivity extends to spontaneouε tumors of non-human mammals. 4. The antibody preparation of claim 1 wherein said antibody preferentially reactε towardε a proliferative compartment of εaid human squamous cell carcinoma. 5. The antibody preparation of claim 1 wherein said antibody preferentially reacts with basal and parabasal mature squamous epithelium. 6. The antibody preparation of claim 5 wherein said mature squamous epithelium is human cervical εquamouε metaplasia. 7. The antibody preparation of claim 1, said preparation being derived from an antibody which is secreted by a hybridoma having ATCC depoεit number HB 10105 or a redone thereof. 8. The antibody preparation of claim 1, εaid preparation compriεing a labelled antibody or binding fragment thereof. 9. A therapeutic agent comprising an antibody which selectively binds to antigens associated with human squamouε cell carcinoma and stem cell populations of stratified epithelium, said antigens including cytoskeletal proteins having molecular weights of approximately 48 to 50 kD and 57 kD, said antibody being associated with a cytotoxic agent, said antibody essentially retaining its specificity. 10. A method of localizing a squamous cell carcinoma which comprises: administering a radiolabelled monoclonal antibody preparation according to claim 1 to a patient; and determining a location of said squamouε cell carcinoma by immunoimaging of εaid radiolabeled monoclonal antibody. 11. The method of claim 10 wherein said monoclonal antibody is secreted by a hybridoma having ATCC deposit number HB 10105 or a derivative thereof. 12. A method of treating squamous cell carcinoma which comprises: administering a therapeutically effective dose to a cancer patient under conditions permitting binding of a monoclonal antibody preparation according to claim 1, said monoclonal antibody being associated with a cytotoxic agent, said monoclonal antibody essentially retaining itε specificity. 13. The method of claim 11 wherein said monoclonal antibody iε εecreted by a hybridoma having ATCC depoεit number HB 10105 or a redone thereof. 14. A method for detecting the presence of a squamous cell carcinoma asεociated antigen in a sample which compriseε incubating a monoclonal antibody preparation according to claim 1 with said sample for a period of time sufficient to permit at least some of the antibody to bind to said antigen and detecting the bound antibody. 15. The method of claim 11 wherein εaid monoclonal antibody iε εecreted by a hybridoma having ATCC depoεit number HB 10105 or a redone thereof. 16. A monoclonal antibody which eεεentially only bindε, to antigens associated with human squamous cell carcinoma and stem cell populations of εtratified epithelium, εaid antigenε include cytoεkeletal proteinε having molecular weightε of approximately 48 to 50kD and 57kD, said monoclonal antibody preferentially reacting with a proliferative compartment of said human squamouε cell carcinoma. 17. The monoclonal antibody of claim 16 wherein said monoclonal antibody preferentially reacts with basal and parabasal mature squamous epithelium. 18. The monoclonal antibody of claim 17 wherein said mature squamous epithelium iε human cervical squamous metaplasia. 19. An antibody preparation comprising an antibody which preferentially bindε to antigenε aεεociated with human squamous cell carcinoma and stem cell populations of stratified epithelium, said antigens being selected from the group consisting of cytoskeletal proteins having molecular weights of approximately 48 to 50 kD and 57 kD. 20. An antibody preparation of claim 1, wherein said monoclonal antibody selectively reacts with thymic epithelium and myoepithelial cells of human breaεt ductε. 21. An antibody preparation of claim 19 which reacts with squamous cells carcinomas of cows, dogs, or catε. 22. An antibody preparation of claim 19 comprising a preparation of antigen-binding fragments or antibody conjugates which bind to human squamouε cell carcinoma and εtem cell populationε of εtratified epithelium, εaid antigens having molecular weights of approximately 48 to 50 kD and 57 kD. 23. A radiolabelled antibody preparation according to claim 18. 24. The radiolabelled antibody preparation according to claim 31 wherein said radiolabelled antibody includes a radionuclide selected from the group conεiεting of 131 I, 125 I, 0 Y, 211 At, 6 Cu, 186 Re, 9m Tc, *-*In, and 67 Ga. 25. An enzyme labelled antibody preparation of claim 8 26. A drug conjugated antibody preparation of claim 1. 27. A proceεε of iεolating antigenε comprising immobilizing an antibody preparation of claim 1 on a solid support, contacting said εolid εupport with a biological sample, εeparating unbound impurities from the solid support, and eluting the antigen in a purified form from the immobilized antibody preparation. 28. A procesε according to claim 27 comprising immobilizing 174H.64 on a εolid εupport, contacting εaid εolid εupport with a biological sample, separating unbound impurities from the solid εupport, and eluting the antigen in an iεolated form from the immobilized 174H.64 preparation. 29. A method of diagnosing squamous cell carcinoma which comprises detection or quantification of the binding reaction of the antibody preparation of claim l and its reaction partner. 30. A method of claim 29 wherein the reaction detected or quantified occurs .in vivo. 31. Use of an antibody preparation according to claim 1 in the manufacture of a composition for the diagnosis or therapy of squamouε cell carcinoma. 32. The therapeutic agent of claim 9 wherein the cytotoxic agent iε daunomycin. 33. The therapeutic agent of claim 9 wherein the cytotoxic agent iε associated with the antibody by an acid- sensitive cis-aconityl spacer.

Inventors: DIENER ERWIN, DING LEI, HAINES DEBORAH M, HONORE LOUIS H, LONGENECKER B MICHAEL, SAMUEL JOHN, STANCZYK-BRZEZINSKA GRAZYNA, WILLANS DAVID, DIENER, ERWIN, DING, LEI, HAINES, DEBORAH, M., HONORE, LOUIS, H., LONGENECKER, B., MICHAEL, SAMUEL, JOHN, STANCZYK-BRZEZINSKA, GRAZYNA, WILLANS, DAVID
Applicants: DIENER ERWIN, DING LEI, HAINES DEBORAH M, HONORE LOUIS H, LONGENECKER B MICHAEL, SAMUEL JOHN, STANCZYK BRZEZINSKA GRAZYNA, WILLANS DAVID, DIENER, ERWIN, DING, LEI, HAINES, DEBORAH, M., HONORE, LOUIS, H., LONGENECKER, B., MICHAEL, SAMUEL, JOHN, STANCZYK-BRZEZINSKA, GRAZYNA, WILLANS, DAVID
Application year: 1990
Main classification: A61K39
IPC codes: A61K38, A61K39, A61K51, A61P35, C07K1, C07K14, C07K16, C07K19, C12N15, C12P21, C12R1, G01N33